A convicted murderer who previously attracted national attention over plans to undergo IVF while in prison has once again become the centre of public controversy after reports she is receiving taxpayer-funded Ozempic treatment and has undergone medically approved eyelid surgery while serving her sentence in Victoria.

The case has reignited a broader debate over prisoner healthcare, the responsibilities of correctional authorities and where the line should be drawn between necessary medical treatment and perceived privileges funded by taxpayers.

According to reports, Alicia Schiller is receiving Ozempic injections while serving a 16-year sentence at Dame Phyllis Frost Centre after gaining significant weight during her imprisonment.

It is also understood she underwent eyelid surgery to remove excess skin associated with a medical condition linked to obesity.

Both treatments have reportedly been approved by prison medical staff following clinical assessment.

Schiller was convicted in 2017 of murdering her Geelong housemate, Tyrelle Evertsen-Mostert, during a drug-fuelled attack over $50. The violent killing shocked Victoria, with the victim leaving behind three children.

The latest revelations have drawn an emotional response from the victim’s family.

Tyrelle Evertsen-Mostert’s mother described the taxpayer-funded treatment as “absolutely ridiculous” and questioned why convicted offenders appeared able to access expensive medications while many law-abiding Australians struggle to afford them.

She also criticised reports that Schiller continued consuming unhealthy food while receiving weight-loss medication.

The controversy follows another highly publicised dispute in late 2024, when Schiller was granted approval to pursue IVF treatment while imprisoned.

That proposal generated widespread public debate about prisoners’ reproductive rights before major IVF providers ultimately indicated they would not provide treatment. The Victorian Government also stated at the time that taxpayers would not fund the IVF procedure itself.

The latest issue, however, concerns routine prison healthcare rather than fertility treatment.

Ozempic was originally developed to help manage type 2 diabetes but has increasingly been prescribed for obesity because of its effectiveness in promoting sustained weight loss.

Outside the public hospital system, many Australians seeking Ozempic for weight management pay hundreds of dollars each month when they do not qualify for subsidised access, making reports of taxpayer-funded treatment for prisoners particularly controversial.

Corrections Victoria has defended its approach without commenting specifically on Schiller’s individual medical circumstances.

Government officials say healthcare decisions inside Victorian prisons are made independently by qualified clinicians according to established medical guidelines rather than political considerations.

They also argue that providing appropriate preventative healthcare can reduce more serious and expensive medical complications later in a prisoner’s sentence.

The issue has become increasingly prominent following concerns over obesity-related illnesses within Victoria’s prison system.

According to reports, prison authorities expanded access to modern weight-loss medications after previous cases highlighted the health risks associated with severe obesity among inmates.

Officials argue that correctional authorities have a legal duty of care to provide healthcare broadly equivalent to community standards for people in custody.

That principle has long formed part of Australia’s correctional health framework and reflects both domestic law and international human rights standards.

Supporters of the current approach argue imprisonment removes a person’s liberty—not their entitlement to medically necessary healthcare.

They contend treatment decisions should be based solely on clinical need rather than the nature of an offender’s crimes.

Critics, however, question whether expensive medications and procedures should be funded when many Australians outside prison face lengthy waiting lists or substantial out-of-pocket medical expenses.

Opposition politicians have argued the case demonstrates a disconnect between public expectations and current correctional healthcare policies.

They say greater transparency is needed regarding which treatments prisoners receive and how those decisions are made using public funds.

Medical experts caution that some procedures described publicly as “plastic surgery” may in fact be medically indicated rather than cosmetic.

Eyelid surgery, for example, can sometimes be recommended where excess skin impairs vision or results from underlying medical conditions, although officials have not released clinical details relating to Schiller’s treatment because of privacy obligations.

Likewise, Ozempic may be prescribed for recognised medical indications under a doctor’s supervision rather than for cosmetic weight loss alone.

The case therefore raises difficult questions extending beyond a single prisoner.

It highlights the ongoing challenge governments face in balancing three competing principles: providing appropriate healthcare to people in custody, ensuring responsible use of taxpayer funds and maintaining public confidence in the justice system.

For the victim’s family, the issue remains deeply personal.

For correctional authorities, it is presented as a matter of clinical independence and legal responsibility.

And for policymakers, the renewed controversy is likely to intensify calls for closer scrutiny of prison healthcare policies as Australians continue debating where society should draw the line between essential medical treatment and perceived privileges for convicted offenders.